Syndax Pharmaceuticals Inc. [SNDX] has traded in a range of $5.35 to $21.97 in the last 1 year. As of this writing, the stock is at $16.13, up 4.40%. To check whether the stock’s short-term amount has a thrust, its good to check stock’s recent movement. Over the last week, SNDX shares are -3.64% down with the monthly amount drift of -4.61% and seems bad in a long time frame.

On 2, September 2020, Syndax Announces Participation at Three Upcoming Investor Conferences. According to news published on Yahoo Finance, Syndax Pharmaceuticals, Inc. (“Syndax,” the “Company” or “we”) (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that members of its management team will participate in three upcoming virtual investor conferences. The details for the three conferences are:.

Analyst Birdseye View:

The most recent analyst activity for Syndax Pharmaceuticals Inc. [NASDAQ:SNDX] stock was on May 22, 2020, when it was Downgrade with a Neutral rating from H.C. Wainwright, which also lowered its 12-month price target on the stock from $25 to $15. Before that, on May 22, 2020, Citigroup Recapitulated a Buy rating and elevated its amount target to $23. On May 18, 2020, Citigroup Downgrade a Neutral rating. On May 11, 2020, H.C. Wainwright Reiterated a Buy rating and increased its price target from $19 to $25. On March 04, 2020, Barclays Initiated an Overweight rating and increased its price target to $15. On January 13, 2020, H.C. Wainwright Reiterated a Buy rating and boosted its amount target on this stock to $17. On March 08, 2019, H.C. Wainwright Reiterated a Buy rating and decreased its target amount on this stock from $22 to $16.

In the past 52 weeks of trading, this stock has oscillated between a low of $5.35 and a peak of $21.97. Right now, according to Wall Street analyst the average 12-month amount target is $23.00. At the most recent market close, shares of Syndax Pharmaceuticals Inc. [NASDAQ:SNDX] were valued at $16.13. According to the average price forecast, investors can expect a potential return of 0.0%.

FUNDAMENTAL ANALYSIS

Syndax Pharmaceuticals Inc. [NASDAQ:SNDX] most recently reported quarterly sales of 379.0 million, which represented growth of 0.00%. This publicly-traded organization’s revenue is $43,343 per employee, while its income is -$1,601,343 per employee. Continuing to look at profitability, this corporation’s Return on Assets, Equity, Whole Principal & invested Principal is sitting at -76.02, -132.43, -134.52 and -131.77 respectively.

If looking now at the Principal structure of this organization, it shows its whole liability to the whole Principal at 2.76 and the whole liability to whole assets at 1.41. It shows enduring liability to the whole principal at 1.29 and enduring liability to assets at 0.01 while looking for an extended time period.

Readers are usually of view to make a close observation to the indicators that support and make resistance before moving to any particular stock. As of now, the company’s stock is sitting at 15.27 points at 1st support level, the second support level is making up to 14.40. But as of 1st resistance point, this stock is sitting at 16.73 and at 17.32 for 2nd resistance point.

Syndax Pharmaceuticals Inc. [SNDX] reported its earnings at -$0.42 per share in the fiscal quarter closing of 6/29/2020. The Analysts for Wall Street were expecting to report its earnings at -$0.45/share signifying the difference of 0.03 and 6.70% surprise value. Comparing the previous quarter ending of 3/30/2020, the stated earnings were -$0.56 calling estimates for -$0.51/share with the difference of -0.05 depicting the surprise of -9.80%.

Important Ratio’s To Watch

Meanwhile, turning our focus to liquidity, the Current Ratio for Syndax Pharmaceuticals Inc. [NASDAQ:SNDX] is 15.40. Likewise, the Quick ratio is also the same, showing Cash ratio at 3.25. Now if looking for a valuation of this stock’s amount to sales ratio it’s 176.47 and it’s amount to book ratio is 7.54.

Insider Stories

The most recent insider trade was by Morrison Briggs, Chief Executive Officer, and it was the purchase of 12500.0 shares on Feb 04.